review
highlight
recent
develop
antibodi
engin
discuss
effect
increas
polyreact
serum
halfliv
engin
antibodi
recent
studi
uncov
wealth
inform
relationship
sequenc
efficaci
antibodi
combin
bioinformat
structur
character
vivo
studi
knowledg
stimul
effort
enhanc
antibodi
breadth
potenc
therapeut
use
although
engin
antibodi
shown
increas
polyreact
short
halfliv
promis
effort
circumv
problem
antibodi
desir
therapeut
due
abil
recogn
target
specif
high
affin
furthermor
abil
antibodi
stimul
fcmediat
effector
function
increas
util
thu
mab
becom
central
strategi
treatment
variou
diseas
use
target
librarybas
approach
antibodi
engin
improv
therapeut
properti
articl
discuss
recent
antibodi
engin
effort
improv
breadth
potenc
antibodi
polyreact
engin
bnab
effect
serum
halflif
explor
along
strategi
overcom
problem
introduc
engin
antibodi
final
advanc
creat
bispecif
reagent
discuss
effect
evad
antibodymedi
respons
due
rapid
mutat
two
glycoprotein
compris
envelop
env
spike
fig
structur
featur
enabl
env
hide
conserv
epitop
includ
shield
hostderiv
carbohydr
conform
mask
steric
occlus
flexibl
variabl
loop
low
number
densiti
envelop
spike
virion
may
also
contribut
abil
evad
antibodi
prevent
igg
bind
simultan
fab
featur
usual
result
product
strainspecif
antibodi
howev
recent
advanc
singlecel
clone
techniqu
led
identif
extrem
potent
broadli
neutral
igg
antibodi
bnab
infect
donor
deliv
passiv
anim
model
infect
bnab
prevent
suppress
infect
prompt
effort
improv
potenc
andor
breadth
order
increas
efficaci
therapeut
character
bnab
structur
bioinformat
approach
identifi
epitop
env
includ
loop
site
membran
proxim
extern
region
mper
site
bridg
fig
review
discuss
engin
effort
creat
potent
antibodi
use
tradit
igg
modifi
architectur
also
consid
engin
effort
result
polyreact
abil
antibodi
bind
one
antigen
lead
autoreact
andor
decreas
vivo
halflif
techniqu
improv
igg
affin
broaden
specif
relat
antigen
improv
express
solubl
includ
comput
techniqu
direct
mutagenesi
introduc
divers
coupl
select
techniqu
exampl
phage
yeast
mrna
ribosom
display
earli
librarybas
engin
effort
improv
antibodi
involv
one
first
bnab
affin
enhanc
nearli
select
bind
librari
phagedisplay
mutant
complementaritydetermin
region
cdr
studi
demonstr
increas
affin
invitro
evolut
could
also
increas
breadth
engin
antibodi
use
modifi
approach
term
sequenti
antigen
plan
improv
affin
breadth
singlechain
variabl
fragment
scfv
librari
antibodi
screen
sequenti
chang
antigen
ultim
identifi
although
antibodi
recent
isol
donor
promis
therapeut
earlier
bnab
librarybas
method
may
import
improv
new
gener
antibodi
introduc
benefici
chang
might
anticip
inspect
antibodyantigen
complex
structur
howev
larg
number
strain
includ
divers
viral
swarm
within
singl
infect
individu
make
difficult
select
antibodi
maintain
breadth
across
viral
librarybas
structuredesignbas
strategi
engin
antibodi
increas
breadth
potenc
even
potent
donorderiv
antibodi
antibodi
engin
may
introduc
polyreact
correl
short
serum
halflif
antibodi
engin
effort
overcom
problem
short
halflif
poor
pharmacokinet
properti
bispecif
chemicallyconjug
antibodi
reagent
provid
altern
strategi
target
multipl
epitop
control
viral
escap
engin
avid
site
ab
epitop
red
ab
epitop
green
ab
epitop
blue
epitop
yellow
epitop
cyan
epitop
pink
mper
epitop
gray
nlink
glycan
shown
grey
stick
ad
potenti
nlink
glycosyl
site
present
coordin
sosip
env
pdb
use
glyprot
repres
bnab
target
epitop
list
strain
increas
bind
one
env
specif
relev
prospect
improv
antibodi
fact
bnab
isol
infect
individu
especi
potent
recent
discov
bnab
often
show
high
level
somat
hypermut
fwr
mutat
requir
bnab
potenc
breadth
may
even
deleteri
potent
antibodi
focu
engin
effort
antibodi
target
use
deriv
heavi
chain
mimic
recognit
structurebas
approach
taken
improv
potent
clonal
variant
structur
mutagenesi
studi
demonstr
fourresidu
insert
within
loop
account
increas
potenc
although
bnab
effect
mimic
fail
fill
hydrophob
pocket
within
mimic
buri
hydrophob
residu
mutant
creat
substitut
residu
improv
potenc
found
trp
phe
tyr
substitut
promis
mutant
show
overal
increas
neutral
potenc
neutral
resist
strain
residu
trp
bnab
less
potent
exampl
demonstr
glytotrp
substitut
posit
possibl
somat
mutat
bnab
lineag
maxim
increas
potenc
substitut
requir
featur
bnab
like
loop
insert
followup
studi
use
structurebas
design
reduc
avail
rout
escap
antibodi
pressur
bioinformat
analysi
identifi
sequenc
correl
resist
antibodi
note
variat
highli
conserv
residu
nngg
motif
name
asn
gli
residu
posit
lead
resist
predict
experiment
verifi
vitro
infect
human
mice
counteract
effect
escap
mutat
ration
design
use
creat
two
new
mutant
lc
introduc
contact
link
glycan
seen
complex
complex
v
hc
remov
steric
clash
substitut
gg
motif
neutral
nearli
virus
improv
bnab
typic
neutral
nearli
strain
vivo
experi
demonstr
viral
escap
longer
found
gg
motif
infect
anim
treat
result
escap
variant
reduc
viral
fit
studi
demonstr
even
highli
somat
mutat
bnab
necessarili
optim
isol
donor
even
imposs
complet
prevent
escap
bnab
might
possibl
drive
evolut
virus
reduc
fit
could
easili
combat
host
defens
mechan
similar
effort
improv
bnab
repres
develop
potent
variant
antibodi
isol
donor
first
pyrosequenc
b
cell
antibodi
gene
transcript
allow
identif
heavi
chain
clonal
variant
close
relat
contain
fourresidu
insert
combin
light
chain
new
bnab
twofold
potent
although
antibodi
engin
per
se
result
illustr
deeper
search
bnab
donor
repertoir
identifi
potent
clonal
rel
exampl
includ
variant
next
amino
acid
evalu
heavi
chain
posit
similar
result
hc
mutant
substitut
larger
residu
includ
trp
tyr
phe
increas
neutral
potenc
breadth
substitut
larg
aromat
residu
result
polyreact
recognit
antigen
substitut
show
least
increas
polyreact
still
increas
potenc
antibodi
light
chain
also
shorten
address
observ
loop
interfer
bind
antibodi
basi
result
screen
light
chain
truncat
modif
tworesidu
ntermin
truncat
well
lc
mutat
select
vivo
experi
mutat
fc
region
improv
plasma
halflif
enhanc
bind
fcrn
ls
mutant
introduc
addit
framework
mutat
revers
solubilityenhanc
mutat
investig
antibodi
select
vivo
halflif
determin
contain
mutat
fiveto
eightfold
potent
neutral
test
strain
vitro
viral
challeng
experi
macaqu
verifi
increas
vitro
potenc
correl
improv
protect
infect
vivo
taken
togeth
exampl
illustr
potenti
improv
activ
bnab
fill
hydrophob
pocket
differ
approach
featur
clonal
relat
antibodi
similar
specif
sometim
combin
one
antibodi
increas
breadth
andor
potenc
exampl
chimer
version
glycandepend
bnab
construct
graft
five
heavi
chain
residu
identifi
contact
complextyp
nlink
glycan
heavi
chain
chimera
gm
exhibit
improv
potenc
neutral
viral
strain
resist
wildtyp
case
member
famili
bnab
target
loop
glycan
posit
three
lc
residu
contact
complex
hybridtyp
nglycan
graft
onto
lc
creat
result
chimer
antibodi
improv
potenc
compar
exampl
graft
residu
contact
complextyp
nglycan
onto
famili
member
favor
highmannos
nglycan
env
posit
seem
allow
antibodi
accommod
differ
type
glycoform
anoth
exampl
neutral
potenc
mper
antibodi
improv
nearli
twofold
engin
mimic
lipidbind
properti
observ
antibodi
rais
foreign
antigen
env
polyreact
autoreact
bind
one
antigen
polyreact
andor
self
protein
autoreact
although
b
cell
autoreact
polyreact
b
cell
receptor
larg
remov
pass
toler
checkpoint
fraction
matur
b
cell
remain
polyreact
autoreact
healthi
individu
polyreact
antibodi
produc
cell
may
gener
use
fight
bacteri
infect
enhanc
phagocytosi
apoptot
cell
inde
bacteri
viral
infect
associ
higher
serum
level
autoreact
polyreact
antibodi
presenc
autoreactivepolyreact
antibodi
associ
infect
year
polyreact
first
character
detail
mper
bnab
bnab
describ
interact
cardiolipin
neg
charg
mitochondri
phospholipid
studi
confirm
bind
env
enhanc
presenc
hostderiv
viral
membran
would
includ
neg
charg
phospholipid
recent
studi
identifi
human
protein
kynureninas
type
inositol
trisphosph
receptor
splice
factor
subunit
potenti
selfantigen
recogn
anoth
mper
antibodi
exhibit
polyreact
standard
assay
yet
bind
tightli
selfantigen
famili
sequenc
similar
member
comprehens
studi
major
env
antibodi
isol
infect
donor
exhibit
bind
self
nonself
antigen
antibodi
show
polyreact
particularli
lipid
antigen
gener
broadli
neutral
antibodi
exhibit
higher
frequenc
polyreact
nonneutr
antibodi
polyreact
may
necessarili
problem
antibodi
especi
common
properti
donorderiv
bnab
howev
correl
increas
polyreact
increas
rate
antibodi
clearanc
vivo
observ
igg
igg
halfliv
normal
extend
beyond
serum
protein
due
interact
fcrn
receptor
protect
serum
igg
default
degrad
pathway
vascular
endotheli
cell
howev
mutat
known
increas
halflif
nonpolyreact
igg
enhanc
interact
fcrn
ls
mutat
introduc
gener
improv
halfliv
polyreact
igg
like
increas
fcrn
function
compens
igg
loss
due
offtarget
bind
absorb
polyreact
igg
lead
rapid
clearanc
antibodi
engin
effort
observ
improv
breadth
potenc
antibodi
lead
increas
polyreact
andor
reduc
solubl
increas
aggreg
propens
studi
describ
mani
hc
substitut
deriv
result
increas
polyreact
decreas
vivo
halfliv
addit
potent
version
gm
exhibit
increas
polyreact
compar
parent
h
mouquet
l
scharf
pj
bjorkman
mc
nussenzweig
unpublish
data
strategi
use
improv
properti
poor
solubl
aggreg
profil
could
lead
polyreact
includ
switch
igg
isotyp
insert
nlink
glycosyl
site
make
target
mutat
reduc
surfaceexpos
hydrophob
residu
exampl
engin
variant
show
increas
breadth
potenc
also
polyreact
poor
pharmacokinet
similar
characterist
observ
case
histidin
substitut
reduc
polyreact
similarli
sever
mutat
intend
elimin
clash
loop
result
variant
increas
polyreact
mutat
identifi
yield
variant
exhibit
favor
pharmacokinet
profil
anoth
studi
structurebas
approach
guid
catalogu
variat
solubl
clonal
rel
use
improv
solubl
nearli
maintain
compar
potenc
import
step
toward
make
antibodi
use
clinic
addit
tradit
igg
architectur
fig
scaffold
use
achiev
bispecif
recognit
small
molecul
conjug
igg
creat
bifunct
reagent
fig
exampl
conjug
cholesterol
light
chain
antimp
bnab
enhanc
potenc
cholesterolmedi
interact
viral
membran
anoth
studi
smallmolecul
inhibitor
viral
entri
aplaviroc
conjug
fc
enhanc
neutral
potenc
earli
exampl
bispecif
reagent
fuse
domain
scfv
version
antibodi
antibodi
recogn
conserv
coreceptorbind
site
expos
result
bind
igg
antibodi
exhibit
limit
neutral
potenc
steric
constraint
bound
target
cell
broadli
neutral
reagent
creat
fuse
variabl
region
antibodi
therebi
solv
steric
problem
epitop
expos
bind
virion
bound
target
cell
fig
reagent
recent
express
chimer
antigen
receptor
car
format
cell
target
kill
cell
later
version
reagent
use
igg
architectur
ntermin
fuse
fab
antibodi
despit
contain
two
moieti
iggbas
reagent
show
increas
potenc
compar
tetraval
fusion
protein
recent
reagent
class
combin
variant
singl
variabl
domain
select
differ
envelop
protein
fig
bispecif
igg
contain
variabl
region
two
differ
igg
produc
use
crossmab
platform
heavi
chain
heterodimer
occur
use
knobintohol
fc
architectur
v
h
v
l
domain
swap
one
half
reagent
ensur
proper
heavi
chainlight
chain
pair
fig
architectur
dual
variabl
domain
construct
attach
second
ig
variabl
domain
ntermin
igg
fig
promis
reagent
class
creat
bnab
anoth
potent
chimer
reagent
construct
fc
fusion
coreceptormimet
peptid
attach
fc
thu
target
receptor
coreceptor
site
env
fig
bispecif
reagent
gener
function
bind
one
envtarget
compon
time
simultan
bind
compon
bispecif
reagent
singl
env
trimer
recent
shown
result
synergist
vitro
neutral
improv
two
three
order
magnitud
suggest
promis
strategi
achiev
potenc
breadth
resist
viral
mutat
synergist
neutral
result
extrem
high
vitro
potenc
also
observ
reagent
combin
antienv
antihost
specif
see
ho
markowitz
issu
exampl
attach
scfv
nterminu
ibalizumab
yield
synergist
reagent
except
potenc
neutral
panel
major
less
mgml
fig
anoth
broad
potent
bispecif
reagent
join
ibalizumab
reagent
neutral
multiclad
pseudoviru
panel
concentr
mgml
although
effect
vaccin
remain
elus
goal
newli
discov
potent
bnab
advanc
engin
antibodi
offer
possibl
improv
passiv
deliveri
strategi
prevent
treat
potent
bnab
could
use
therapeut
lower
concentr
thu
reduc
cost
andor
product
time
increas
number
patient
treat
lower
potenti
immunogen
side
effect
relat
bnab
administr
also
remain
need
creat
reagent
combat
viral
mutat
natur
sequenc
divers
may
possibl
identifi
common
pathway
viral
escap
use
structurebas
design
engin
resist
pathway
librarybas
strategi
design
enhanc
affin
also
lead
increas
breadth
block
escap
bispecif
reagent
chemic
conjug
reagent
offer
way
target
multipl
site
prevent
viral
escap
strategi
combat
divers
although
increas
polyreact
associ
improv
bnab
may
necessarili
danger
polyreact
correl
shorten
plasma
halflif
repres
indic
reagent
need
optim
improv
biophys
pharmacokinet
properti
recent
success
creat
bispecif
conjug
engin
antibodi
reagent
minim
polyreact
may
import
therapeut
particularli
gene
therapi
strategi
vectormedi
gene
transfer
see
balasz
baltimor
issu
use
deliv
antibodi
antibodylik
reagent
